Tweet
Euro Surveill. Azole-resistant Aspergillus fumigatus in the environment of northern Italy, May 2011 to June 2012
[Source: Eurosurveillance, full page: (LINK). Abstract, edited.]
Eurosurveillance, Volume 19, Issue 12, 27 March 2014 / Research articles
Azole-resistant Aspergillus fumigatus in the environment of northern Italy, May 2011 to June 2012
A Prigitano<SUP>1</SUP>, V Venier<SUP>1</SUP>, M Cogliati<SUP>1</SUP>, G De Lorenzis<SUP>2</SUP>, M C Esposto<SUP>1</SUP>, A M Tortorano <SUP>1</SUP>
<SUP></SUP>
<SUP>1</SUP>Dipartimento di Scienze Biomediche per la Salute, Universit? degli Studi di Milano, Milano, Italy - 2Dipartimento di Scienze Agrarie e Ambientali, Universita` degli Studi di Milano, Milano, Italy
______
Citation style for this article: Prigitano A, Venier V, Cogliati M, De Lorenzis G, Esposto MC, Tortorano AM. Azole-resistant Aspergillus fumigatus in the environment of northern Italy, May 2011 to June 2012. Euro Surveill. 2014;19(12):pii=20747. Available online: http://www.eurosurveillance.org/View...rticleId=20747
Date of submission: 11 July 2013
______
In recent years acquired azole resistance in Aspergillus fumigatus has been increasingly reported and a dominant mechanism of resistance (TR34/L98H) was found in clinical and environmental isolates. The aim of the present study was to investigate the prevalence of azole resistance in environmental A. fumigatus isolates collected in northern Italy. A. fumigatus grew from 29 of 47 soil samples analysed. Azole-resistant isolates were detected in 13% (6/47) of the soil samples and in 21% (6/29) of the soil samples containing A. fumigatus. High minimal inhibitory concentrations (MIC) of itraconazole (≥16 mg/L) and posaconazole (≥0.5 mg/L) were displayed by nine isolates from six different soil samples, namely apple orchard (1 sample), rose pot compost (2 samples), and cucurbit yields (3 samples). Seven isolates had a MIC=2 mg/L of voriconazole. Seven of nine itraconazole and posaconazole resistant isolates harboured the same TR<SUB>34</SUB>/L98H mutation of cyp51A. These findings, together with the occurrence of resistant clinical isolates, suggest that azole resistance should be considered in primary patient care.
-
-------
Eurosurveillance, Volume 19, Issue 12, 27 March 2014 / Research articles
Azole-resistant Aspergillus fumigatus in the environment of northern Italy, May 2011 to June 2012
A Prigitano<SUP>1</SUP>, V Venier<SUP>1</SUP>, M Cogliati<SUP>1</SUP>, G De Lorenzis<SUP>2</SUP>, M C Esposto<SUP>1</SUP>, A M Tortorano <SUP>1</SUP>
<SUP></SUP>
<SUP>1</SUP>Dipartimento di Scienze Biomediche per la Salute, Universit? degli Studi di Milano, Milano, Italy - 2Dipartimento di Scienze Agrarie e Ambientali, Universita` degli Studi di Milano, Milano, Italy
______
Citation style for this article: Prigitano A, Venier V, Cogliati M, De Lorenzis G, Esposto MC, Tortorano AM. Azole-resistant Aspergillus fumigatus in the environment of northern Italy, May 2011 to June 2012. Euro Surveill. 2014;19(12):pii=20747. Available online: http://www.eurosurveillance.org/View...rticleId=20747
Date of submission: 11 July 2013
______
In recent years acquired azole resistance in Aspergillus fumigatus has been increasingly reported and a dominant mechanism of resistance (TR34/L98H) was found in clinical and environmental isolates. The aim of the present study was to investigate the prevalence of azole resistance in environmental A. fumigatus isolates collected in northern Italy. A. fumigatus grew from 29 of 47 soil samples analysed. Azole-resistant isolates were detected in 13% (6/47) of the soil samples and in 21% (6/29) of the soil samples containing A. fumigatus. High minimal inhibitory concentrations (MIC) of itraconazole (≥16 mg/L) and posaconazole (≥0.5 mg/L) were displayed by nine isolates from six different soil samples, namely apple orchard (1 sample), rose pot compost (2 samples), and cucurbit yields (3 samples). Seven isolates had a MIC=2 mg/L of voriconazole. Seven of nine itraconazole and posaconazole resistant isolates harboured the same TR<SUB>34</SUB>/L98H mutation of cyp51A. These findings, together with the occurrence of resistant clinical isolates, suggest that azole resistance should be considered in primary patient care.
-
-------